Intellectual Property in Israel

Israel is one of the most IP-intensive economies in the world, with a dense concentration of technology companies, life sciences firms, and R&D centres. Protecting intellectual property in Israel requires navigating a legal system that blends common law traditions with civil law influences, administered through dedicated registries and courts. Failure to register or enforce rights promptly can result in permanent loss of exclusivity, costly litigation, or the erosion of competitive advantage in a market where innovation cycles are short. This article covers the full spectrum of IP protection in Israel - trademarks, patents, copyright, trade secrets, and enforcement - giving international business owners a practical roadmap.

Israel's intellectual property law rests on several distinct statutes, each governing a separate category of rights. The Patents Law, 5727-1967 (as amended) establishes the conditions for patentability, the rights of patent holders, and the procedures before the Israel Patent Office (IPO). The Trade Marks Ordinance [New Version], 5732-1972 governs trademark registration and protection. Copyright in Israel is regulated by the Copyright Law, 5768-2007, which modernised the prior British Mandate-era framework and brought Israeli law broadly in line with international standards under the Berne Convention. Trade secrets are protected under the Commercial Torts Law, 5759-1999, specifically through the provisions on misappropriation of trade secrets.

Israel is a member of the Paris Convention, the Patent Cooperation Treaty (PCT), the Madrid Protocol for international trademark registration, and the WIPO Copyright Treaty. This membership allows international applicants to use familiar multi-jurisdictional filing routes to obtain protection in Israel, and vice versa.

The Israel Patent Office (IPO), operating under the Ministry of Justice, is the primary administrative body for patents, trademarks, and design registrations. The IPO examines applications, maintains public registers, and handles opposition proceedings. For copyright, there is no registration requirement - protection arises automatically upon creation of an original work - but the IPO does maintain a voluntary copyright deposit system that can be useful as evidence in disputes.

A non-obvious risk for international companies is the assumption that a PCT application or a Madrid Protocol designation automatically results in Israeli protection without further local procedural steps. In practice, each route requires compliance with Israeli-specific requirements, including translation obligations and local agent appointment, and missing deadlines at the national phase entry stage can be fatal to the application.

A trademark in Israel is defined under the Trade Marks Ordinance as any mark used or proposed to be used to distinguish goods or services of one person from those of another. The definition is broad and covers words, logos, shapes, colours, sounds, and combinations thereof. Three-dimensional marks and non-traditional marks are registrable, though they face a higher evidentiary threshold to demonstrate distinctiveness.

The registration process begins with filing an application at the IPO, specifying the mark, the applicant's details, and the relevant Nice Classification classes. The IPO conducts a formal examination followed by a substantive examination for distinctiveness and conflicts with prior marks. If the examiner raises objections, the applicant has the opportunity to respond, typically within 90 days of the office action. If the application is accepted, it is published in the Trade Marks Journal for a three-month opposition period, during which any third party may file an opposition.

Registration, once granted, is valid for ten years from the filing date and is renewable indefinitely for successive ten-year periods. Non-use of a registered mark for three consecutive years creates vulnerability to cancellation proceedings brought by third parties.

A common mistake made by international applicants is filing only in the classes directly corresponding to their core product, neglecting related service classes or defensive classes that competitors might exploit. In Israel's technology sector, where products and services frequently overlap, a narrow filing strategy can leave significant gaps in protection.

The Madrid Protocol route is available for applicants who already hold a home-country registration or application. Designation of Israel through Madrid results in a national phase examination by the IPO, and refusals must be addressed within the standard examination timelines. The Madrid route offers cost efficiencies for multi-country filings but requires careful monitoring of the central attack period - if the base application or registration is cancelled within five years of the international registration date, the Israeli designation falls with it.

Costs for trademark registration in Israel are moderate by international standards. Professional fees for a straightforward single-class application typically start from the low thousands of USD, with additional costs for multi-class filings, responses to office actions, or opposition proceedings.

To receive a checklist for trademark registration and protection in Israel, send a request to info@vlo.com.

A patent in Israel grants the holder an exclusive right to exploit the invention for 20 years from the filing date, subject to annual renewal fees. The Patents Law, 5727-1967 requires that an invention be novel, involve an inventive step, and be capable of industrial application - criteria that align with the European Patent Convention standard, though Israeli examiners apply their own interpretive approach.

Israel does not have a utility model system. This means that incremental innovations that might qualify for utility model protection in Germany or China must meet the full patentability standard in Israel, or be protected through other means such as trade secrets or contractual restrictions.

The PCT route is the most common entry point for international applicants seeking Israeli patent protection. The national phase entry deadline in Israel is 30 months from the priority date. Missing this deadline is generally fatal - there is no reinstatement mechanism for late national phase entries in Israel, unlike some other jurisdictions. This is a critical procedural trap for companies managing large PCT portfolios.

Once in the national phase, the IPO conducts a substantive examination. Israel has a deferred examination system: applicants may request examination within 42 months of the filing date (or priority date). This deferred examination option allows applicants to assess commercial viability before incurring full prosecution costs, but it also means that competitors can monitor published applications and adjust their strategies accordingly.

Israel's life sciences and pharmaceutical sector generates a significant volume of patent disputes. The Patents Law contains provisions on compulsory licensing and on the relationship between patent protection and regulatory approval - the so-called patent linkage system. Under amendments to the Patents Law and the Pharmacists Ordinance, generic drug manufacturers must notify patent holders when seeking marketing approval for a patented drug, triggering a defined period during which the patent holder may seek an injunction. This mechanism is broadly analogous to the Hatch-Waxman framework in the United States, though with important procedural differences.

A practical scenario: a European pharmaceutical company holds a PCT-derived Israeli patent on a drug compound. A local generic manufacturer files for marketing approval and serves notice under the patent linkage provisions. The patent holder has 45 days from receipt of notice to file an infringement action in the District Court if it wishes to trigger the automatic stay on generic approval. Missing this window means the generic may proceed to market while litigation is still pending, significantly altering the commercial dynamics of the dispute.

Patent prosecution costs in Israel, including IPO fees and professional fees, typically start from several thousand USD for a straightforward application, with significantly higher costs for complex biotechnology or software-related inventions that require extensive prosecution.

Copyright protection in Israel arises automatically under the Copyright Law, 5768-2007, upon the creation of an original work. The categories of protected works include literary works, artistic works, dramatic works, musical works, sound recordings, films, broadcasts, and typographical arrangements. The originality threshold in Israeli copyright law is relatively low - the work must originate from the author and involve a minimal degree of creativity, but it need not be novel in the patent sense.

The term of copyright protection is generally the life of the author plus 70 years, consistent with the Berne Convention standard. For works made for hire, the term is 70 years from the date of creation or first publication, whichever is earlier.

A non-obvious risk for technology companies operating in Israel is the treatment of software copyright. Software is protected as a literary work under the Copyright Law, but the scope of protection covers the expression of the code, not the underlying ideas or algorithms. This means that a competitor who independently develops functionally equivalent software without copying the code does not infringe copyright, even if the commercial result is identical. Companies relying solely on copyright to protect software functionality are exposed to this gap.

Trade secret protection under the Commercial Torts Law, 5759-1999 fills part of this gap. A trade secret is defined as business information, including technical information, that is not publicly known, that provides a commercial advantage to its holder, and that the holder takes reasonable steps to keep confidential. The law prohibits misappropriation of trade secrets, which includes unauthorised acquisition, use, or disclosure.

The 'reasonable steps' requirement is de facto more demanding than it appears on paper. Israeli courts have declined to protect information where the plaintiff could not demonstrate active confidentiality measures - such as non-disclosure agreements, access controls, employee training, and documented confidentiality policies. Many international companies underappreciate this requirement and assume that internal awareness of confidentiality is sufficient. It is not.

A practical scenario: a multinational technology company establishes an R&D centre in Israel. Several engineers leave to join a competitor and bring with them detailed knowledge of a proprietary algorithm. If the company did not have signed NDAs with those employees, did not restrict access to the algorithm on a need-to-know basis, and did not document its confidentiality procedures, it will face serious difficulties establishing trade secret protection in Israeli courts, regardless of the actual value of the information.

To receive a checklist for trade secret protection and employee IP agreements in Israel, send a request to info@vlo.com.

IP disputes in Israel are litigated primarily before the District Courts, which have exclusive jurisdiction over patent, trademark, copyright, and trade secret claims. The District Court in Tel Aviv handles the majority of commercial IP cases given the concentration of technology and life sciences companies in the Tel Aviv metropolitan area. The Supreme Court of Israel (Beit Mishpat Elyon) hears appeals on points of law.

The IPO also has jurisdiction over certain administrative proceedings, including trademark oppositions, cancellation applications, and patent validity challenges. Administrative proceedings before the IPO are generally faster and less expensive than court litigation, making them a useful tactical tool - particularly for clearing the register of conflicting marks or challenging weak patents held by competitors.

Interim injunctions are available in Israeli IP litigation and are a critical enforcement tool, particularly in cases involving ongoing infringement or imminent harm. The standard for obtaining an interim injunction requires the applicant to demonstrate a prima facie case, a real risk of irreparable harm, and that the balance of convenience favours granting the order. Israeli courts apply these criteria rigorously, and a poorly prepared application - without detailed evidence of the right, the infringement, and the harm - will be refused.

The risk of inaction is particularly acute in trademark and copyright cases. Delay in seeking an interim injunction can be interpreted by the court as evidence that the harm is not truly irreparable, weakening the applicant's position. In practice, applicants who wait more than a few weeks after discovering infringement before filing for interim relief face a significantly higher burden of justification.

Remedies available in Israeli IP litigation include permanent injunctions, damages (actual or statutory), account of profits, delivery up and destruction of infringing goods, and publication of the judgment. The Copyright Law, 5768-2007 provides for statutory damages of up to approximately 100,000 NIS per work infringed without proof of actual loss, which can be a significant deterrent in cases involving multiple works. The exact ceiling is subject to periodic adjustment and should be verified at the time of filing.

A practical scenario: a software company discovers that a local distributor has been selling unlicensed copies of its product. The company has two primary options. It can file a civil claim in the District Court seeking damages and an injunction, or it can file a criminal complaint with the Israeli Police, since copyright infringement for commercial purposes is a criminal offence under the Copyright Law. The criminal route is slower and less controllable, but it carries reputational consequences for the infringer and may prompt a faster settlement. The civil route gives the rights holder more control over the process and the remedies sought.

Litigation costs in Israel vary considerably depending on complexity. For a straightforward trademark infringement case, legal fees typically start from the low tens of thousands of USD. Complex patent litigation in the life sciences sector can run to several hundred thousand USD or more over a multi-year proceeding. Cost-benefit analysis is essential before committing to litigation, particularly where the infringing party has limited assets.

We can help build a strategy for IP enforcement in Israel, including assessment of available remedies and procedural routes. Contact info@vlo.com.

Israel's Patents Law, 5727-1967 contains specific provisions on employee inventions that differ materially from the default rules in many other jurisdictions. Under Section 132 of the Patents Law, an invention made by an employee in the course of employment, using the employer's resources, or in a field related to the employer's business, belongs to the employer. However, the employee retains a right to equitable remuneration if the invention generates significant commercial benefit disproportionate to the employee's salary and conditions of employment.

This equitable remuneration right cannot be waived in advance by contract. Any contractual provision purporting to extinguish the employee's right to additional compensation before the invention is made is void under Israeli law. This is a significant departure from the approach in many common law jurisdictions, where employment contracts routinely assign all IP rights to the employer without residual compensation obligations.

In practice, the equitable remuneration right is rarely exercised successfully by employees, because the threshold - demonstrating that the invention generated exceptional commercial benefit disproportionate to the employment relationship - is high. However, the risk is real for companies whose Israeli R&D centres produce breakthrough inventions that generate substantial global revenue. A non-obvious risk is that this exposure is not limited to Israeli employees: if the invention is made in Israel, the Israeli law applies regardless of the governing law clause in the employment contract.

The Office of the Chief Scientist (now operating as the Israel Innovation Authority) administers grants and incentives for R&D conducted in Israel. Companies that receive Innovation Authority funding are subject to restrictions on the transfer of IP developed with that funding outside of Israel. These restrictions are governed by the Encouragement of Research, Development and Technological Innovation in Industry Law, 5744-1984 (as amended). Transferring funded IP abroad without approval requires payment of a royalty or a lump sum to the Innovation Authority, calculated on the basis of the grant received. Failure to comply with these restrictions can result in repayment obligations and reputational consequences with the Innovation Authority.

A common mistake made by foreign acquirers of Israeli technology companies is failing to conduct adequate due diligence on Innovation Authority funding history. If the target company received grants and the acquirer intends to transfer IP to a foreign holding structure post-acquisition, the Innovation Authority approval process must be factored into the transaction timeline and economics. This process can take several months and may involve conditions that affect deal structure.

For companies structuring R&D agreements with Israeli universities or research institutions, the Technology Transfer companies (such as Yissum at the Hebrew University or Ramot at Tel Aviv University) hold IP rights generated by academic researchers and license them to industry. Negotiating these licenses requires understanding the standard terms used by Israeli technology transfer offices, which differ from US or European academic licensing norms in several respects, including milestone structures and sublicensing rights.

To receive a checklist for IP due diligence and R&D agreement structuring in Israel, send a request to info@vlo.com.

What is the biggest practical risk for a foreign company relying on an unregistered trademark in Israel?

An unregistered trademark in Israel can receive limited protection under the tort of passing off, which requires proof of goodwill, misrepresentation, and damage. However, this protection is significantly weaker than registered trademark rights and is difficult to enforce against a third party who registers a similar mark in good faith. If a competitor registers a mark that conflicts with your unregistered mark before you do, you may face costly opposition or cancellation proceedings, and in the interim you lose the ability to stop the competitor's use. The cost and uncertainty of relying on unregistered rights far exceeds the cost of early registration, particularly in a market as competitive as Israel's technology sector.

How long does patent litigation in Israel typically take, and what are the financial implications?

Patent litigation before the Israeli District Court typically takes between three and six years from filing to final judgment at first instance, with appeals to the Supreme Court adding further time. This timeline has significant financial implications: a patent holder must sustain litigation costs over a prolonged period while the infringing product may continue to be sold. Interim injunctions can mitigate this risk if obtained early, but they require a strong prima facie case and carry the risk of a cross-undertaking in damages if the injunction is later found to have been wrongly granted. Companies should assess whether the commercial value of the patent justifies the litigation investment, and whether licensing or settlement offers a more efficient resolution.

When should a company choose administrative proceedings at the IPO rather than court litigation for an IP dispute in Israel?

Administrative proceedings at the IPO - such as trademark opposition, cancellation, or patent validity challenges - are generally faster, less expensive, and more focused on the specific legal question of registrability or validity than full court litigation. They are the preferred route when the primary objective is to prevent a competitor from obtaining or maintaining a registration, rather than to obtain damages or an injunction. However, the IPO cannot award monetary compensation or grant injunctive relief against ongoing infringement. Where the dispute involves active commercial harm - ongoing sales of infringing products, misappropriation of trade secrets, or breach of a license agreement - court proceedings are necessary. In complex disputes, both routes may be pursued simultaneously.

Israel's IP framework is sophisticated, internationally integrated, and actively enforced. The combination of strong statutory rights, an experienced judiciary, and a highly competitive technology market makes IP strategy a business-critical function for any company operating or investing in Israel. The key risks - missed registration deadlines, inadequate trade secret procedures, Innovation Authority funding restrictions, and employee invention rights - are all manageable with proper legal preparation. Reactive approaches to IP protection consistently produce worse outcomes than proactive registration and enforcement strategies.

Our law firm Vetrov & Partners has experience supporting clients in Israel on intellectual property matters. We can assist with trademark and patent registration, IP due diligence in M&A transactions, trade secret protection programmes, enforcement proceedings before the District Courts and the IPO, and R&D agreement structuring. To receive a consultation, contact: info@vlo.com.